Evidence map›Paper›PMID 35992881›Full record

ArticleFrontiers in oncology2022

Anti-Migratory Effect of Dipotassium Glycyrrhizinate on Glioblastoma Cell Lines: Microarray Data for the Identification of Key MicroRNA Signatures.

Gabriel Alves Bonafé, Jéssica Silva Dos Santos, Anna Maria Alves de Piloto Fernandes, Jussara Vaz Ziegler, Fernando Augusto Lima Marson, Thalita Rocha, Patricia de Oliveira Carvalho, Manoela Marques Ortega

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gabriel Alves BonaféLaboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Jéssica Silva Dos SantosLaboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Anna Maria Alves de Piloto FernandesMultidisciplinary Research Laboratory, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Jussara Vaz ZieglerVerdi Cosmetics Limited Liability Company, Joanópolis, São Paulo, Brazil.
Fernando Augusto Lima MarsonLaboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Thalita RochaPost Graduate Program in Biomaterials and Regenerative Medicine, Faculty of Medical Sciences and Health, Pontifical Catholic University of São Paulo, Sorocaba, São Paulo, Brazil.
Patricia de Oliveira CarvalhoMultidisciplinary Research Laboratory, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Manoela Marques OrtegaLaboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Post Graduate Program in Health Science, São Francisco University, Bragança Paulista, São Paulo, Brazil.
Universidade São Francisco · BRPontifícia Universidade Católica de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nuclear factor kappa B (NF-κB) pathway has been reported to be responsible for the aggressive disease phenomenon observed in glioblastoma (GBM). Dipotassium glycyrrhizinate (DPG), a dipotassium salt of glycyrrhizic acid isolated from licorice, has recently demonstrated an anti-tumoral effect on GBM cell lines U87MG and T98G through NF-κB suppression by

Indexed as

dipotassium glycyrrhizinateglioblastomametastasis formation inhibitionmicroRNA signaturemiR-4443 and miR-3620nuclear factor kappa B pathway

Identifiers

PMID35992881
PMCPMC9382584
OpenAlexW4289544652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.